Author name: Leonardo Arias

The planned logistics site, near a principal manufacturing facility, will handle global distribution of Boston Scientific’s medical devices.

Un estudio reciente de huesos de micromamíferos con una innovadora técnica basada en luminiscencia indica que el Homo erectus, aunque no sabía producir fuego, lo introdujo en la cueva de Wonderwerk, en Sudáfrica, hace entre 1,07 y 1,79 millones de años.   El …

Roche and Nurix Therapeutics will advance their BTK degrader for chronic lymphocytic leukemia, as well as immunology and neurology indications.

After Revolution Medicine’s groundbreaking data drop in April, its Tango-partnered combination approach has demonstrated what analysts called “unprecedented” results for 12 patients with pancreatic cancer, teeing up a late-stage study.

Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.

After a $625 million IPO, the biggest ever in biotech, obesity-focused Kailera Therapeutics is readying a commercial strategy that puts patients at the center.

While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.

Over two years of treatment, Eli Lilly’s triple-G drug cut body weight by more than 30% in certain patients with obesity, cementing the pharma’s position as the frontrunner in the metabolic space.

Much work needs to be done for Pfizer to be able to catch up to the weight-loss frontrunners, according to Guggenheim Partners, but new data from Metsera’s lead asset could set the pharma apart from competitors with a monthly injection.

Si te piden que pienses en la revolución científica del siglo XVII, el primer nombre que te vendrá a la mente será, casi con total seguridad, Sir Isaac Newton. Sin embargo, a la sombra del gigante de la gravedad vivió un hombre cuya mente era tan brillante, ca&oacu …